Ionis Pharmaceuticals reported fresh Phase 2 CELIA data for diranersen in early Alzheimer’s disease and secured European Commission approval to expand TRYNGOLZA’s label to severe hypertriglyceridemia,...
Source LinkIonis Pharmaceuticals reported fresh Phase 2 CELIA data for diranersen in early Alzheimer’s disease and secured European Commission approval to expand TRYNGOLZA’s label to severe hypertriglyceridemia,...
Source Link
Comments